多靶标基因并行检测技术为肿瘤个体化治疗提供新模式  

Multiple target gene detection technologies provide a new dimension for personalized cancer therapy

作　　者：蔡贞[1] 郑磊[1] 

机构地区：[1]南方医科大学南方医院检验医学科,广东广州510515

出　　处：《分子诊断与治疗杂志》2013年第6期361-366,354,共6页Journal of Molecular Diagnostics and Therapy

基　　金：国家自然科学基金(81101609);广东省自然科学基金(S2011010003840);广东省医学科研基金(A2013375);国家特色专业临床检验(TS2483)

摘　　要：随着人类基因组学和药物基因组学的发展,肿瘤个体化诊疗已由愿景变成了现实。肿瘤的发生发展是一个多基因参与、多信号通路激活的复杂生物学过程,多靶标并行检测可一次同时对多个肿瘤个体化诊疗相关靶标进行检测,为临床医生制定适宜的个体化诊疗方案提供更为全面的信息。本文仅就近年出现的可实现多靶标并行检测的主要技术-液相芯片技术和新一代测序技术做简要的述评,并简述多靶标并行检测在质量控制方面应遵循的基本原则。Along with the development of human genomics and pharmacogenomics, the personalized diagnosis and treatment of cancer has translated from vision into reality. The occurrence and development of malignant tumors is a complicated biological process involving multiple genes and signaling pathways. Parallel detection technologies are capability of detection of multiple target genes simultaneously, which provide more comprehensive information for clinical doctors to make personalized treatment program. This article will briefly introduce the new developed multiple target genes parallel detection technology, liquidchip technology and next-generation sequencing technology and discuss the basic principles of quality control involved in these technologies.

关 键 词：肿瘤 个体化诊疗 多靶标并行检测技术 

分 类 号：R730.5[医药卫生—肿瘤]